INNOCAN PHARMA Corp
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INNPF research report →
About the company
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems by integrating cannabidiol (CBD) with diverse pharmaceutical ingredients. Its operations extend across the United States, Poland, France, and other international markets. The company actively pursues research and development into CBD-loaded exosomes for treating conditions like COVID-19, as well as advancing CBD-infused liposomes.
- CEO
- Iris Bincovich
- IPO
- 2020
- Employees
- 11
- HQ
- Calgary, AB, CA
Price Chart
- Market Cap
- $7.20M
- P/E
- -7.47
- P/S
- 0.44
- P/B
- 2.13
- EV/EBITDA
- -8.55
- Div Yield
- 0.00%
- Gross Margin
- 89.81%
- Op Margin
- -10.00%
- Net Margin
- -5.95%
- ROE
- -31.76%
- ROIC
- -26.92%
- Revenue
- $26.61M · -9.60%
- Net Income
- $-1,124,000 · 38.71%
- EPS
- $-0.25 · 40.48%
- Op Income
- $-1,255,000
- FCF YoY
- 130.05%
- 52W High
- $14.26
- 52W Low
- $1.60
- 50D MA
- $13.01
- 200D MA
- $13.01
- Beta
- -0.27
- Avg Volume
- 395
Get TickerSpark's AI analysis on INNPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our INNPF coverage
Recent articles, reports, and earnings notes.
No research on INNPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INNPF report →Similar companies
Peers in the same neighborhood.